DOI QR코드

DOI QR Code

Outcome of High Dose AmpicillinSulbactam and Colistin Combination Therapy for Treating VentilatorAssociated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii: a Pilot Study

Carbapenem내성 Acinetobacter baumannii로 인한 인공호흡기연관 폐렴 환아에서 고용량 Ampicillin-Sulbactam 과 Colistin 항균제 병합요법의 치료적 예후: 예비 연구

  • Jeong, Seong Hee (Department of Pediatrics, Pusan National University Children's Hospital) ;
  • Kim, Young A (Department of Pediatrics, Pusan National University Children's Hospital) ;
  • Choi, Go-eun (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan) ;
  • Park, Su Eun (Department of Pediatrics, Pusan National University Children's Hospital)
  • 정성희 (부산대학교 어린이병원 소아청소년과) ;
  • 김영아 (부산대학교 어린이병원 소아청소년과) ;
  • 최고은 (부산카톨릭대학교 진단검사의학과) ;
  • 박수은 (부산대학교 어린이병원 소아청소년과)
  • Received : 2019.08.14
  • Accepted : 2019.11.17
  • Published : 2020.04.25

Abstract

Purpose: This pilot study aimed to evaluate the efficacy of high dose ampicillin-sulbactam and colistin combination therapy for ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) in the pediatric intensive care unit of Pusan National University Children's Hospital. Methods: We retrospectively reviewed 17 pediatric patients with VAP caused by CRAB from June 2017 to August 2018. Ten (58.8%) patients were treated with high dose ampicillin-sulbactam and colistin combination therapy (combination therapy group), whereas 7 were treated with colistin only or with various combinations with or without colistin (other antibiotics group). Clinical and bacteriological outcomes were compared between the groups. Results: The mean duration of fever after antibiotic use was 1.30±1.70 days in the combination therapy group and 1.71±1.49 days in the other antibiotics group. The mean duration of days for negative conversion of endotracheal aspirate bacterial culture after antibiotic therapy was 3.40±1.71 days in the combination therapy group and 11.80±8.86 days in the other antibiotics group. The mortality rate within 30 days of antibiotic therapy was 1/10 (10%) in the combination therapy group and 3/7 (42.9%) in the other antibiotics group. Conclusions: High dose ampicillin-sulbactam and colistin combination therapy as early antibiotic treatment in VAP caused by CRAB in children could improve clinical outcomes.

목적: Carbapenem-resistant Acinetobacter baumannii (CRAB)에 의한 인공호흡기연관 폐렴(ventilator-associated pneumonia, VAP)의 치료에 있어 고용량 ampicillin-sulbactam과 colistin의 병합요법 치료효과를 살펴보기 위한 예비 연구이다. 방법: 2017년도 6월부터 2018년도 8월까지 17명의 CRAB VAP 환자를 후향적으로 분석하였다. 10명(58.8%)의 환자는 고용량 ampicillin-sulbactam과 colistin 병합요법(병합치료군)으로 치료받았으며, 나머지 7명은 colistin 단독치료를 하였거나 colistin을 포함 또는 미포함하는 다양한 항균제의 병합치료(기타치료군)를 하였다. 본 연구는 두 그룹간의 임상 및 세균학적 결과를 비교하였다. 결과: 병합치료군에서 항균제 사용 후 발열기간은 1.30±1.70일이었고, 기타치료군에서는 1.71±1.49일이었다. 기관내관 흡인물 검체에서 균이 음전 될 때까지의 평균 기간은 병합치료군에서 3.40±1.71일 기타치료군에서 11.80±8.86일이었다(P=0.030). 항균제 치료 30일 이내 사망률은 병합치료균에서 1/10 (10%)이고 기타치료군에서 3/7 (42.9%)이었다. 결론: 소아의 CRAB에 의한 인공호흡기연관 폐렴 환자에서 고용량 ampicillin-sulbactam과 colistin의 병합요법이 임상적 예후를 개선시킬 수 있을 것으로 기대된다.

Keywords

References

  1. Pogue JM, Neelakanta A, Mynatt RP, Sharma S, Lephart P, Kaye KS. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis 2014;59 Suppl 6:S388-93. https://doi.org/10.1093/cid/ciu594
  2. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014;33:1311-22. https://doi.org/10.1007/s10096-014-2070-6
  3. Kim YA, Park YS. Epidemiology and treatment of antimicrobial-resistant gram-negative bacteria in Korea. Korean J Intern Med 2018;33:247-55. https://doi.org/10.3904/kjim.2018.028
  4. Bae IK, Jeong SH, Lee K. Carbapenem-resistant Acinetobacter baumannii. Korean J Clin Microbiol 2012;15:1-8. https://doi.org/10.5145/KJCM.2012.15.1.1
  5. Park SY, Lee EJ, Kim T, Yu SN, Park KH, Lee MS, et al. Early administration of appropriate antimicrobial agents to improve the outcome of carbapenem-resistant Acinetobacter baumannii complex bacteraemic pneumonia. Int J Antimicrob Agents 2018;51:407-12. https://doi.org/10.1016/j.ijantimicag.2017.10.018
  6. Lee HJ, Lee DG. Carbapenem-resistant Enterobacteriaceae: recent updates and treatment strategies. J Korean Med Assoc 2018;61:281-9. https://doi.org/10.5124/jkma.2018.61.4.281
  7. Logan LK. Carbapenem-resistant enterobacteriaceae: an emerging problem in children. Clin Infect Dis 2012;55:852-9. https://doi.org/10.1093/cid/cis543
  8. Makris D, Petinaki E, Tsolaki V, Manoulakas E, Mantzarlis K, Apostolopoulou O, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study. Indian J Crit Care Med 2018;22:67-77. https://doi.org/10.4103/ijccm.IJCCM_302_17
  9. Hsu AJ, Tamma PD. Treatment of multidrug-resistant gram-negative infections in children. Clin Infect Dis 2014;58:1439-48. https://doi.org/10.1093/cid/ciu069
  10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI document M100-S25. Wayne: Clinical and Laboratory Standards Institute, 2015.
  11. Skrupky LP, McConnell K, Dallas J, Kollef MH. A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria. Crit Care Med 2012;40:281-4. https://doi.org/10.1097/CCM.0b013e31822d7913
  12. Mularoni A, Bertani A, Vizzini G, Gona F, Campanella M, Spada M, et al. Outcome of transplantation using organs from donors infected or colonized with carbapenem-resistant gram-negative bacteria. Am J Transplant 2015;15:2674-82. https://doi.org/10.1111/ajt.13317
  13. Choi SJ, Moon CJ, Chun YH, Yoon JS, Kim HH, Kim JT, et al. PRISM III in a pediatric intensive care unit with multiple disease entities. Korean J Crit Care Med 2011;26:123-7. https://doi.org/10.4266/kjccm.2011.26.3.123
  14. Ko KS, Choi Y, Lee JY. Old drug, new findings: colistin resistance and dependence of Acinetobacter baumannii. Precis Future Med 2017;1:159-67. https://doi.org/10.23838/pfm.2017.00184
  15. Lee K, Yong D, Jeong SH, Chong Y. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J 2011;52:879-91. https://doi.org/10.3349/ymj.2011.52.6.879
  16. Kim MJ, Lee HJ, Son SH, Huh JW. Outbreak of Acinetobacter septicemia in a neonatal intensive care unit. Korean J Pediatr 2006;49:494-9. https://doi.org/10.3345/kjp.2006.49.5.494

Cited by

  1. Colistin/vancomycin : Acute kidney injury: case report vol.1762, pp.1, 2020, https://doi.org/10.1007/s40278-019-64858-9